Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 8.79
- Piotroski Score 5.00
- Grade Buy
- Symbol (BLFS)
- Company BioLife Solutions, Inc.
- Price $22.33
- Changes Percentage (9.06%)
- Change $1.86
- Day Low $19.97
- Day High $22.39
- Year High $28.88
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $30.00
- High Stock Price Target $30.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.42
- Trailing P/E Ratio -14.3
- Forward P/E Ratio -14.3
- P/E Growth -14.3
- Net Income $-66,427,000
Income Statement
Quarterly
Annual
Latest News of BLFS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioLife Solutions Inc (BLFS) Q3 2024 Earnings Call Highlights: Strategic Divestitures and ...
The earnings call transcript details post-SSAE sale financials, with 60% adjusted gross margin and 13% EBITDA for the first half of 2024. Future growth is expected in 2025, focusing on cell processing...
By Yahoo! Finance | 6 days ago -
BioLife Solutions (BLFS) Surpassed Revenue and Earnings-Per-Share Expectations in Q2
Conestoga Capital Advisors' Q2 2024 investor letter discusses the market moderation, with small-cap stocks underperforming. BioLife Solutions, Inc. (NASDAQ:BLFS) was highlighted as a top pick with a s...
By Yahoo! Finance | 3 months ago -
A Look At The Intrinsic Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
The analyst price target for BLFS is slightly higher than the fair value estimate. Using a discounted cash flow model, the company's value is calculated to be US$1.1b, indicating the stock is trading ...
By Yahoo! Finance | 4 months ago
